Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials
Open Access
- 25 February 2026
- journal article
- Published by Elsevier in JHEP Reports
- Vol. 8 (5) , 101791
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health and Care Research
- MSD
- Bayer Yakuhin
- Université Catholique de Louvain
- Biocompatibles UK
This publication has 34 references indexed in Scilit:
- Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2025
- The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRTCardioVascular and Interventional Radiology, 2020
- Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based ApproachHepatology, 2019
- Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular CarcinomaCardioVascular and Interventional Radiology, 2018
- Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenibInvestigational New Drugs, 2016
- Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenibHepatology, 2015
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trialHepatology, 2014
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial designHepatology, 2013
- Transarterial therapies for hepatocellular carcinoma (HCC): A long way towards standardizationJournal of Hepatology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009